A lot of reporting in the treatment space over the past few days, and we appreciate the Kaiser Family Foundation for aggregating the stories so we can provide them to you here.
- Drug Overdose from Fentanyl Spinning Out of ControlThe New York Times: The First Count Of Fentanyl Deaths In 2016: Up 540% In Three Years
Drug overdoses killed roughly 64,000 people in the United States last year, according to the first governmental account of nationwide drug deaths to cover all of 2016. It’s a staggering rise of more than 22 percent over the 52,404 drug deaths recorded the previous year — and even higher than The New York Times’s estimate in June, which was based on earlier preliminary data. (Katz, 9/2)
- Controversial Nomination for Director of Office of National Drug Control Policy
Stat: Trump Nominates Republican Congressman Tom Marino As Drug Czar
President Trump on Friday nominated Rep. Tom Marino (R-Pa.) to lead the Office of National Drug Control Policy as the nation’s “drug czar,” months after he had officially withdrawn from consideration. Marino, an attorney who has served in the House of Representatives since 2011, has a lengthy track record of supporting enforcement-side drug policy as well as improved drug treatment. (Facher, 9/2)
- Abuse of OTC Drugs Can Be Harmful As Well
The New York Times: Opioids Aren’t The Only Pain Drugs To Fear
Last month, a White House panel declared the nation’s epidemic of opioid abuse and deaths “a national public health emergency,” a designation usually assigned to natural disasters. A disaster is indeed what it is, with 142 Americans dying daily from drug overdoses, a fourfold increase since 1999, more than the number of people killed by gun homicides and vehicular crashes combined. A 2015 National Survey on Drug Use and Health estimated that 3.8 million Americans use opioids for nonmedical reasons every month. (Brody, 9/4)
- Private Equity Continues Investment in Drug Treatment Facilities in 2017
The Wall Street Journal: Private-Equity Pours Cash Into Opioid-Treatment Sector
Private-equity firms are piling into a new business opportunity: the opioid addiction crisis. Drawn by soaring demand, expanded insurance coverage and the chance to consolidate a highly fragmented market, firms plowed $2.9 billion into treatment facilities last year, up from $11.4 million in 2011, according to research firm PitchBook Data Inc. The number of private-equity deals rose to 45 from 25. (Whalen and Cooper, 9/2)
- The Science of Addiction – Do We Finally Have the Tech to See Inside the Brain?
The Washington Post: Addiction And The Brain
Today’s war on drugs isn’t fought by first ladies or celebrity advocates. Armed with MRI machines, electromagnetic pulses and experimental drugs, scientists are on the battle’s front lines. In the cover story of September’s National Geographic, Fran Smith explores the different fronts of a war being fought in laboratories and universities all over the world. Armed with the tools of science and with the help of people who struggle with addictions to substances and self-destructive behavior, researchers are working to unravel the mysteries of the addicted brain. (Blakemore, 9/2)
- Crystalmeth Continues Its Journey Outside Rural America and Into Our Cities.
The Wall Street Journal: Drug Traffickers Push Meth Into New York City
Mexican traffickers are supplying the New York City area with methamphetamine, attempting to create new clients in what historically has been a weak market for the drug. “The Mexican cartels have been sending loads up to New York and telling traffickers, ‘See if you can get customers,’ ” said James Hunt, special agent-in-charge of the Drug Enforcement Administration’s New York division. “They want to create an addict population.” (Ramey, 9/4)
- Vivitrol Marketing Continues to Capture the Attention of State Funded Programs.
New Orleans Times-Picayune: Louisiana Prisons Start Administering New Drug To Treat Opioid Addicts
The use of Vivitrol is the latest trend in opioid treatment. In the first quarter of 2017, Vivitrol sales totaled $58 million, a 33 percent increase over the previous year, according to a June report by ProPublica. Several state prisons, including those in Illinois, Wyoming and Wisconsin, started administering the drug to inmates last year. Even more drug courts and local jails are using it: ProPublica tallied up more than 450 public Vivitrol initiatives in 39 states. (O’Donoghue, 9/1)
- The War on Drugs and Caring for the Addicted Inmate.
The Baltimore Sun: Baltimore County Facing Higher Costs For Inmate Care Due To Addiction, Mental Health Services
The cost of providing medical care for inmates at the Baltimore County jail in Towson is rising more than 50 percent — several million dollars a year — due primarily to an increase in inmates and detainees with opioid addiction, mental illness or chronic diseases. The County Council is set to vote Tuesday on a contract for a private company, PrimeCare Medical, to manage medical, dental and behavioral health treatment for the jail’s roughly 1,200 inmates. (Wood, 9/5)
- Recovery High Schools – the Continuation of Recovery Educated-Based Programs.
St. Louis Public Radio: New Missouri High School Will Help Teens Struggling With Addiction Avoid Temptations
Teens who struggle with drug and alcohol abuse face many temptations after complete treatment. A new private high school opening soon in suburban St. Louis will offer them an educational environment free of some of those potential triggers. (Delaney, 9/4)
- Is Insurance Also to Blame for Addiction?
Idaho Statesman: Insurers Tell Idaho Pain Patients: Try More-Addictive Drugs
In at least three cases, patients with Regence BlueShield of Idaho plans were denied Radnovich’s choice of a Butrans patch — a long-acting version of the opioid buprenorphine that is “Schedule III,” with a “moderate to low potential for physical and psychological dependence.” Instead of the patch, Regence was willing to pay for a fentanyl patch or morphine tablets. (Dutton, 9/4)
Jeffrey C. Lynne is a South Florida native, representing individuals and business entities relating to licensing, accreditation, regulatory compliance, business structure, marketing, real estate, zoning and litigation pertaining to substance abuse treatment facilities and sober living residences. Mr. Lynne has been recognized across the region as a leader in progressive public dialogue about the role that substance abuse treatment has within our communities and the fundamental need and right to provide safe and affordable housing for those who are both in treatment for addiction and alcoholism as well as those who are established in their recovery.
Latest posts by Jeffrey Lynne (see all)
- Google Quietly Explores Addiction Treatment in Ohio - March 7, 2019
- What We Are Reading This Week - March 6, 2019
- U.S. attorney sues to stop supervised injection sites in Philadelphia - February 8, 2019